Key points are not available for this paper at this time.
Wacker Chemie, the German specialty chemicals firm, has opened a new facility for making messenger RNA (mRNA) –based active ingredients for medicines such as vaccines and cancer drugs at its site in Halle, Germany. The facility, which cost over 100 million, has four mRNA production lines. It more than triples Wacker's production capacity at Halle, to over 200 million vaccine doses annually. The company plans to open a biotech center in Munich later this year.
Alex Scott (Mon,) studied this question.